查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992414

化療引起的噁心嘔吐治療市場：按藥物類別、給藥途徑、治療方法、分銷管道、最終用戶、嘔吐風險和患者年齡層分類－2026年至2032年全球市場預測

Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class, Route Of Administration, Therapy Type, Distribution Channel, End User, Emetic Risk, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，化療引起的噁心和嘔吐治療市場價值 33.4 億美元，預計到 2026 年將成長至 35.5 億美元，複合年成長率為 6.75%，到 2032 年將達到 52.8 億美元。

主要市場統計數據
基準年 2025 33.4億美元
預計年份：2026年 35.5億美元
預測年份 2032 52.8億美元
複合年成長率 (%) 6.75%

一份高階主管的總結報告，闡述了當前臨床挑戰、以患者為中心的治療結果以及塑造止吐治療路徑的策略挑戰。

化療引起的噁心和嘔吐仍然是接受細胞毒性或分子標靶癌症治療的患者最嚴重的副作用之一。臨床醫生在選擇止吐方案時，需要不斷權衡療效、耐受性和患者的生活品質，而保險公司和醫療機構則面臨著成本、可及性和用藥依從性等挑戰。同時，藥理學、支持治療和給藥方法的進步正在重新思考治療方案和臨床路徑。

確定臨床實踐、藥物開發、報銷模式和病人參與的變革性變化，以重新定義止吐治療的提供方式。

化療引起的噁心嘔吐的治療格局正在經歷一系列變革，這些變革正在影響臨床實踐、研發重點和支付方的決策。臨床上，人們越來越重視預防而非應對突發症狀，多機制療法的應用日益廣泛，並且更加重視以指引為基礎的治療。這些變化反映了人們對嘔吐機制的更深入理解，以及對能夠最大限度減少後續併發症和非計劃醫療支出的治療方法的日益青睞。

2025 年美國關稅調整的累積經濟、政策和供應鏈影響，以及這些影響對止吐治療取得的影響。

政策變化，例如關稅調整，會對藥品供應鏈、採購慣例以及最終的臨床應用產生連鎖反應。美國於2025年實施的關稅調整改變了進口成本和行政流程，對製造商、經銷商和醫療保健採購負責人都產生了影響。這些影響不僅體現在直接採購操作中，還體現在關鍵支持性治療藥物的策略採購決策和庫存管理實踐中。

實用的細分見解揭示了藥物類別、給藥途徑、治療方法、分銷管道、最終用戶、嘔吐風險和年齡層如何影響臨床選擇。

精細的細分方法揭示了影響臨床選擇和操作偏好的因素，這些因素涵蓋藥物類別、給藥途徑、治療方法、分銷管道、最終用戶、嘔吐風險和患者年齡等多個方面。從藥物類別觀點，受體標靶藥物在預防中重度嘔吐的治療方法中佔據主導地位。在5-HT3受體拮抗劑中，醫護人員會根據起效時間、持續時間和耐受性對Granisetron、Ondansetron、Palonosetron和雷莫司瓊進行比較，而地塞米松和Methylprednisolone等皮質類固醇仍作為基礎輔助性治療使用。多巴胺受體拮抗劑在搶救治療和特定適應症中仍然有效，其中甲氧氯普胺和丙氯拉嗪因其明確的臨床作用而繼續使用。此外，NK1受體拮抗劑，包括Aprepitant和福沙吡坦，是高風險通訊協定聯合治療的重要一環。

影響美洲、歐洲、中東、非洲和亞太地區醫療服務取得、處方趨勢、監管變化和供應韌性的區域趨勢。

區域趨勢對監管方式、進入途徑和供應穩定性有顯著影響。在美洲，醫療保健系統高度重視實證預防措施和整合式診療路徑，以促進患者遵循指引建議的治療方案。此外，完善的採購系統支援合約和庫存策略，從而穩定了藥物的供應。在歐洲、中東和非洲，監管差異和不同的報銷模式造就了不同的准入途徑。有些地區優先採用集中採購，而有些地區則依賴區域處方集決策，這影響了新製劑和聯合治療的採用率。

競爭資訊重點在於領先的止吐藥研發公司的創新、夥伴關係、產品線定位和商業化策略。

止吐藥產業的企業競爭格局取決於漸進式創新、產品組合廣度、合作策略和商業化能力等因素的綜合作用。如果擁有獨特配方、緩釋特性或新型給藥系統的研發企業能夠將這些特性轉化為醫療機構用藥依從性和營運效率的顯著提升，那麼這些企業就能獲得相對優勢。同樣重要的是，透過策略合作拓展分銷網路、共同開發聯合治療或整合輔助性數位健康工具來監測患者症狀和用藥依從性。

為經營團隊提供切實可行的策略建議，以改善臨床結果、增強供應韌性、最佳化定價和提升病患服務。

致力於提升治療效果和業務永續營運的領導者應優先採取一系列措施，協調臨床、商業和供應鏈目標。首先，必須在所有醫療機構中標準化預防性給藥通訊協定，以最大限度地減少給藥方案選擇的差異，並確保根據嘔吐風險分層提供一致的護理。統一臨床路徑可以減少不必要的護理差異，並支援可預測的採購和庫存計劃。

一套全面的調查方法，包括資料收集、資訊來源檢驗、分析框架、檢驗程序以及與專家合作，以獲得可靠的見解。

本報告的分析整合了多項一手和二手調查的數據，以確保獲得多角度且檢驗的見解。資料收集包括對同儕審查文獻、監管文件和臨床指南的系統性回顧，以及對臨床醫生、藥房經理、供應鏈經理和行業高管的結構化訪談。這種混合方法使我們能夠捕捉到與決策相關的定量模式和定性背景資訊。

將策略挑戰、持續挑戰和成長路徑進行明確整合，以改善止吐治療的患者療效和營運韌性。

本報告提出的綜合分析強調了目前面臨的幾項挑戰：治療方法的選擇應基於嘔吐風險和患者病情；必須積極主動地管理供應鏈韌性；以及產生與臨床實踐相關的證據對於更廣泛地應用至關重要。其他挑戰還包括協調臨床醫生、支付方和採購機構等相關人員的獎勵，並確保在不同區域背景下公平地獲得治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：化療引起的噁心嘔吐治療市場：依藥物類別分類

  • 5-HT3受體拮抗劑
    • Granisetron
    • Ondansetron
    • Palonosetron
    • 拉莫塞特龍
  • 皮質類固醇
    • 地塞米松
    • Methylprednisolone
  • 多巴胺受體拮抗劑
    • 甲氧氯普胺
    • 丙氯拉嗪
  • NK1受體拮抗劑
    • Aprepitant
    • 福沙匹坦

第9章：化療引起的噁心嘔吐治療市場：依化療途徑分類

  • 靜脈
  • 口服

第10章：化療－治療方法分類的市場

  • 聯合治療
    • 雙聯療法
      • 5-HT3 和 NK1
      • 5-HT3受體拮抗劑和類固醇
      • NK1受體拮抗劑和類固醇
    • 三聯聯合治療
  • 單藥治療

第11章：化療引起的噁心嘔吐治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：化療引起的噁心嘔吐治療市場：依最終使用者分類

  • 居家醫療
  • 醫院
  • 專科診所

第13章：化療引起的噁心嘔吐治療市場及嘔吐風險分析

  • 高的
  • 低的
  • 溫和的
  • 緩和

第14章：化療－以患者年齡分類的市場

  • 成人版
  • 兒童

第15章：化療引起的噁心嘔吐治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：化療引起的噁心嘔吐治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：化療引起的噁心嘔吐治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國化療引起的噁心和嘔吐治療市場

第19章：中國化療引起的噁心嘔吐藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Mundipharma International Limited
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-3204321AF679

The Chemotherapy Induced Nausea & Vomiting Treatment Market was valued at USD 3.34 billion in 2025 and is projected to grow to USD 3.55 billion in 2026, with a CAGR of 6.75%, reaching USD 5.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.34 billion
Estimated Year [2026] USD 3.55 billion
Forecast Year [2032] USD 5.28 billion
CAGR (%) 6.75%

A focused executive primer defining contemporary clinical challenges, patient-centric outcomes, and strategic imperatives shaping antiemetic therapy pathways

Chemotherapy induced nausea and vomiting remains one of the most consequential adverse effects experienced by patients undergoing cytotoxic or targeted oncology therapies. Clinicians continue to balance efficacy, tolerability, and patient quality of life when selecting antiemetic regimens, while payers and providers navigate cost, access, and adherence considerations. In parallel, advances in pharmacology, adjunctive supportive care, and administration modalities are reshaping therapeutic choices and clinical pathways.

The modern treatment landscape increasingly emphasizes individualized approaches that account for emetic risk, comorbidities, and patient-specific factors such as age and prior response to antiemetics. As a result, stakeholders across clinical practice, pharmacy operations, and commercial strategy require clear, evidence-informed perspectives on drug classes, regimen composition, and delivery settings. This introduction consolidates core themes that persistently influence therapeutic decision-making and frames the subsequent analysis in terms of clinical imperatives, stakeholder incentives, and operational constraints.

Moving forward, the report navigates the intersection of clinical innovation, regulatory developments, and supply chain dynamics. It highlights how incremental improvements in antiemetic efficacy, shifts in administration preference, and evolving care delivery models collectively affect patient experience and institutional readiness. The intent here is to set a pragmatic foundation that aligns clinician priorities with organizational objectives, enabling informed choices that protect patients' quality of life while maintaining operational viability.

Identifying transformative shifts across clinical practice, drug development, reimbursement models, and patient engagement that are redefining antiemetic care delivery

The treatment landscape for chemotherapy induced nausea and vomiting is undergoing a sequence of transformative shifts that touch clinical practice, development priorities, and payer decision-making. Clinically, a stronger emphasis on prevention ahead of breakthrough management has driven adoption of multi-mechanistic regimens and reinforced guideline-driven care. These shifts reflect improved understanding of emetic pathways and a growing preference for regimens that minimize downstream morbidity and unplanned care utilization.

From a development perspective, pharmaceutical strategies prioritize formulations and combinations that enhance adherence and enable outpatient administration. This trend is complemented by innovation in oral agents and extended half-life formulations that reduce dosing complexity. Simultaneously, regulatory emphasis on real-world effectiveness and patient-reported outcomes is shaping trial design and post-approval evidence generation, encouraging sponsors to embed pragmatic endpoints that resonate with clinicians and payers alike.

Payer and provider systems are converging on value-based criteria that stress both clinical outcomes and total cost of care. Consequently, stakeholders are reassessing formulary placement and contracting strategies to favor therapies that demonstrate consistent prophylactic benefit. At the same time, patient engagement initiatives and digital health tools are being deployed to improve adherence and symptom reporting, which helps clinicians titrate therapy more precisely and detect breakthrough nausea earlier.

Taken together, these shifts are not isolated; they are mutually reinforcing. Improved agents enable ambulatory care models, which in turn change distribution and procurement practices. As the landscape evolves, organizations that integrate clinical, commercial, and operational perspectives will be best positioned to convert scientific advances into sustained improvements in patient experience.

Cumulative economic, policy and supply chain ramifications of the 2025 United States tariff adjustments and effects on antiemetic treatment access

Policy changes such as tariff adjustments can have a cascade of effects across pharmaceutical supply chains, procurement practices, and ultimately clinical access. United States tariff changes implemented in 2025 introduced modifications to import costs and administrative complexity that ripple through manufacturers, contract distributors, and institutional buyers. These effects manifested not only in direct procurement operations but also in strategic sourcing decisions and inventory management practices for critical supportive care medicines.

In practical terms, procurement teams faced shorter planning horizons and increased emphasis on local sourcing where feasible, prompting some health systems to diversify supplier relationships. Manufacturers and contract distributors responded by reassessing production footprints, increasing engagement with domestic contract manufacturing organizations, and in some cases prioritizing higher-margin formulations. These operational responses aimed to mitigate exposure to tariff-related cost shifts and to maintain continuity of supply.

Clinicians and pharmacy leaders adapted by refining ordering cadence, reinforcing stock rotation policies, and expanding therapeutic substitution protocols to preserve continuity of care. At the same time, payers and procurement entities examined contractual terms and rebate structures to ensure predictable access to guideline-recommended regimens. Importantly, these adjustments were not uniformly disruptive; institutions with advanced supply chain analytics and close manufacturer partnerships were able to maintain steady access with minimal clinical impact.

Overall, the policy environment in 2025 underscored the importance of supply chain visibility, diversified sourcing strategies, and proactive engagement between manufacturers and health systems. These lessons have durability beyond immediate policy cycles and should inform long-term planning for essential supportive care therapies.

Actionable segmentation insights revealing how drug classes, administration routes, therapy regimens, distribution channels, end users, emetic risk and age cohorts drive clinical choice

A nuanced segmentation lens reveals the drivers of clinical choice and operational preference across drug class, route, therapy type, distribution, end user, emetic risk, and patient age. When considering drug class selection, receptor-targeted agents dominate prophylactic strategies for moderately and highly emetogenic regimens; within 5-HT3 receptor antagonists, practitioners weigh differences among granisetron, ondansetron, palonosetron and ramosetron based on onset, duration and tolerability, while corticosteroids such as dexamethasone and methylprednisolone continue to be foundational adjuncts. Dopamine receptor antagonists remain relevant for rescue and select indications, with metoclopramide and prochlorperazine retained for their clear clinical roles, and NK1 receptor antagonists, including aprepitant and fosaprepitant, are integral to combination regimens for high-risk protocols.

Route of administration is a critical operational consideration; the choice between intravenous and oral delivery shapes inpatient workflows, outpatient infusion center throughput, and home care feasibility. Intravenous administration offers immediate bioavailability and is often favored in acute settings, while oral options support ambulatory care and greater patient convenience. Treatment strategy is further refined through therapy type selection, where monotherapy may be appropriate for low risk scenarios but combination therapy-either dual or triple regimens-dominates prophylaxis for higher emetic risk. Dual regimens commonly combine 5-HT3 and NK1 agents, 5-HT3 agents with steroids, or NK1 agents with steroids, each pairing chosen to target complementary pathways and maximize prophylactic benefit.

Distribution channel considerations influence accessibility and adherence. Hospital pharmacies play a central role for inpatient and infusion center needs, retail pharmacies support community dispensing, and online pharmacies are increasingly used for repeat dosing and home delivery models. End user contexts-home care settings, hospitals, and specialty clinics-each impose distinct constraints and opportunities: home care demands simplified regimens and clear patient education materials, hospitals require integration with electronic prescribing and formulary controls, and specialty clinics prioritize regimen efficacy aligned with oncologic protocols.

Emetic risk stratification-classified as high, moderate, low or minimal-remains the primary clinical axis around which regimen intensity is determined, and patient age groups, whether adult or pediatric, require tailored dosing, formulation selection and tolerability considerations. Pediatric patients often need age-appropriate formulations and dosing strategies that reduce administration burden, whereas adult cohorts accommodate a broader range of oral and intravenous options. In sum, rigorous segmentation supports precise therapeutic alignment: selecting the appropriate agent and regimen for a patient's emetic risk and care setting while accounting for distribution and age-related considerations leads to better adherence and clinical outcomes.

Regional dynamics shaping access, prescribing trends, regulatory evolution, and supply resiliency across Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert substantial influence over regulatory approaches, access pathways, and supply resilience. In the Americas, health systems display a strong emphasis on evidenced-based prophylaxis and integrated care pathways that promote adherence to guideline-recommended regimens; procurement sophistication supports contracting arrangements and inventory strategies that stabilize access. Across Europe, Middle East & Africa, regulatory heterogeneity and variable reimbursement models create differentiated pathways to access, with some jurisdictions prioritizing centralized procurement and others relying on localized formulary decision-making, which impacts how quickly new formulations or combinations are adopted.

In Asia-Pacific, rapid expansion of oncology services and growing emphasis on ambulatory care are accelerating demand for oral and long-acting antiemetic options. Regional manufacturing footprints and supplier diversification in this area also influence product availability and pricing dynamics. Across all regions, localized clinical practice patterns, national guideline endorsements, and health system procurement capabilities drive how therapies are implemented in practice. For example, countries with robust outpatient oncology infrastructure are more likely to favor oral regimens that support home administration, whereas regions with constrained outpatient capacity may rely more heavily on infusion-based strategies.

Supply chain considerations differ by region as well; jurisdictions with established domestic production capacity exhibit greater resilience to import disruptions, while those reliant on international suppliers are more sensitive to policy shifts and logistical constraints. Clinicians and health system leaders must therefore calibrate procurement strategies, formulary decisions, and patient education efforts to local realities, leveraging regional partnerships and cross-border collaboration where possible to maintain continuity of care and equitable access.

Competitive intelligence highlighting innovation, partnerships, pipeline positioning and commercialization strategies of major antiemetic developers

Competitive dynamics among companies in the antiemetic space are defined by a combination of incremental innovation, portfolio breadth, partnership strategies, and commercialization execution. Developers with differentiated formulations, extended-release profiles, or novel delivery systems gain relative advantage when those attributes translate into measurable adherence improvements or workflow efficiencies for providers. Equally important are strategic alliances that broaden distribution reach, enable co-development of combination approaches, or integrate adjunctive digital health tools to monitor patient symptoms and adherence.

Generic manufacturers and specialty pharmaceutical companies play complementary roles: generics provide price-competitive access for established agents, while specialty firms focus on next-generation formulations, combination products, or indications that extend prophylactic coverage. Pipeline activity often centers on combination packaging, novel oral formulations that simplify dosing, and improvements in tolerability, reflecting an industry focus on reducing the clinical burden of nausea while enabling care in ambulatory and home settings.

Commercial strategy matters; companies that deploy targeted clinician education, real-world evidence generation, and value communications aligned with payer priorities achieve stronger formulary positioning. Moreover, manufacturing resilience and supply chain transparency are critical differentiators, as buyers increasingly demand predictable supply and collaborative contingency planning. Ultimately, firms that integrate clinical evidence, operational reliability, and clear value propositions are best positioned to influence treatment protocols and capture sustained clinical trust.

Practical strategic recommendations for leaders to improve clinical outcomes, shore up supply resilience, refine pricing and enhance patient services

Leaders seeking to strengthen therapeutic impact and operational resilience should pursue a set of prioritized actions that align clinical, commercial, and supply chain objectives. First, standardize prophylaxis protocols across care settings to minimize variability in regimen selection and ensure that emetic risk stratification drives consistent practice. Aligning clinical pathways reduces unwarranted practice variation and supports predictable procurement and inventory planning.

Second, diversify sourcing and build contractual mechanisms that ensure continuity of supply. Long-term supplier agreements, regional manufacturing partnerships, and flexible contracting terms help institutions respond to policy shifts and logistical disruptions. In parallel, enhance supply chain visibility through analytics that forecast consumption, monitor inventory levels in near real time, and alert stakeholders to potential constraints before they impact patient care.

Third, prioritize regimen simplification where clinically appropriate. Favoring formulations and combinations that reduce dosing complexity supports adherence in home care settings and decreases administration burden in outpatient infusion centers. Complement regimen optimization with robust patient education and digital adherence supports that improve symptom reporting and early intervention for breakthrough nausea.

Finally, invest in evidence generation that resonates with payers and clinicians. Real-world effectiveness studies, patient-reported outcome data, and comparative effectiveness analyses provide persuasive inputs for formulary discussions and guideline updates. By integrating these strategic initiatives-protocol standardization, supply diversification, regimen simplification, and targeted evidence generation-leaders can both elevate patient outcomes and reduce operational risk.

Comprehensive research methodology covering data collection, source triangulation, analysis frameworks, validation steps and expert engagement for robust insights

The analysis underpinning this report synthesizes multiple primary and secondary research streams to ensure triangulated and validated insights. Data collection combined systematic review of peer-reviewed literature, regulatory documentation, and clinical guidelines with structured interviews of clinicians, pharmacy leaders, supply chain managers, and industry executives. This mixed-methods approach enabled the capture of both quantitative patterns and qualitative context that inform decision-making.

Analytical frameworks included comparative regimen assessment, distribution channel mapping, and stakeholder impact analysis. These frameworks guided evaluation of drug classes, administration routes, and therapy types in relation to clinical outcomes and operational feasibility. Validation steps included cross-referencing interview findings with published guidelines and supply chain data, seeking convergence across independent sources to minimize bias and enhance reliability.

Expert engagement involved advisory consultations with clinicians and pharmacy directors to test assumptions and prioritize areas of operational risk. Where ambiguity emerged, targeted follow-up interviews and additional desk research were deployed to refine conclusions. Together, these methods produced a coherent evidence base that supports pragmatic recommendations and highlights where further bespoke research would add value.

Conclusive synthesis of strategic imperatives, enduring challenges and growth pathways to elevate patient outcomes and operational resilience in antiemetic care

The synthesis presented here underscores several enduring imperatives: therapies should be selected to match emetic risk and patient context; supply chain resilience must be actively managed; and evidence generation tailored to real-world practice is essential for broader adoption. Persistent challenges include aligning stakeholder incentives across clinicians, payers, and procurement entities, and ensuring equitable access across diverse regional contexts.

Opportunities are clear. Simplified regimens and patient-friendly formulations support the transition to ambulatory and home-based care models, while targeted evidence that emphasizes patient-reported outcomes can shift payer calculus toward broader coverage. Operationally, investments in predictive inventory analytics and supplier diversification reduce exposure to policy-driven disruptions and support continuous care delivery.

In closing, success will require coordinated action: clinical teams must standardize approaches based on risk stratification; procurement leaders must secure adaptable supply arrangements; and commercial teams must communicate value in terms that matter to clinicians and payers. By aligning these elements, organizations can achieve sustained improvement in patient experience and operational performance in the management of chemotherapy induced nausea and vomiting.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Drug Class

  • 8.1. 5-HT3 Receptor Antagonists
    • 8.1.1. Granisetron
    • 8.1.2. Ondansetron
    • 8.1.3. Palonosetron
    • 8.1.4. Ramosetron
  • 8.2. Corticosteroids
    • 8.2.1. Dexamethasone
    • 8.2.2. Methylprednisolone
  • 8.3. Dopamine Receptor Antagonists
    • 8.3.1. Metoclopramide
    • 8.3.2. Prochlorperazine
  • 8.4. NK1 Receptor Antagonists
    • 8.4.1. Aprepitant
    • 8.4.2. Fosaprepitant

9. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Therapy Type

  • 10.1. Combination Therapy
    • 10.1.1. Dual Regimen
      • 10.1.1.1. 5-HT3 And NK1
      • 10.1.1.2. 5-HT3 And Steroid
      • 10.1.1.3. NK1 And Steroid
    • 10.1.2. Triple Regimen
  • 10.2. Monotherapy

11. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Chemotherapy Induced Nausea & Vomiting Treatment Market, by End User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Emetic Risk

  • 13.1. High
  • 13.2. Low
  • 13.3. Minimal
  • 13.4. Moderate

14. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Patient Age Group

  • 14.1. Adult
  • 14.2. Pediatric

15. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Chemotherapy Induced Nausea & Vomiting Treatment Market

19. China Chemotherapy Induced Nausea & Vomiting Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca plc
  • 20.8. Baxter International Inc.
  • 20.9. Cipla Inc.
  • 20.10. Dr. Reddy's Laboratories Ltd.
  • 20.11. Eisai Co., Ltd.
  • 20.12. Eli Lilly and Company
  • 20.13. GlaxoSmithKline plc
  • 20.14. Helsinn Healthcare S.A.
  • 20.15. Heron Therapeutics, Inc.
  • 20.16. Jazz Pharmaceuticals plc
  • 20.17. Kyowa Hakko Kirin Co., Ltd.
  • 20.18. Merck & Co., Inc.
  • 20.19. Mundipharma International Limited
  • 20.20. Novartis AG
  • 20.21. Ono Pharmaceutical Co., Ltd.
  • 20.22. Pfizer Inc.
  • 20.23. Roche Holding AG
  • 20.24. Sanofi S.A.
  • 20.25. Sun Pharmaceutical Industries Ltd.
  • 20.26. Takeda Pharmaceutical Company Limited
  • 20.27. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GCC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC C